CR11828A - Compuestos novedosos activos como antagonistas de receptor muscarínico - Google Patents

Compuestos novedosos activos como antagonistas de receptor muscarínico

Info

Publication number
CR11828A
CR11828A CR11828A CR11828A CR11828A CR 11828 A CR11828 A CR 11828A CR 11828 A CR11828 A CR 11828A CR 11828 A CR11828 A CR 11828A CR 11828 A CR11828 A CR 11828A
Authority
CR
Costa Rica
Prior art keywords
compounds
novedous
new
muscarinic
receiver antagonists
Prior art date
Application number
CR11828A
Other languages
English (en)
Inventor
Paul Alan Glossop
Charlotte Alice Louise Lane
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CR11828A publication Critical patent/CR11828A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de fórmula, a procesos e intermedios para su preparación, a su uso como antagonistas muscarínicos y a composiciones farmacéuticas que los cntienen.
CR11828A 2008-07-15 2010-12-07 Compuestos novedosos activos como antagonistas de receptor muscarínico CR11828A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8072608P 2008-07-15 2008-07-15

Publications (1)

Publication Number Publication Date
CR11828A true CR11828A (es) 2011-01-10

Family

ID=41139473

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11828A CR11828A (es) 2008-07-15 2010-12-07 Compuestos novedosos activos como antagonistas de receptor muscarínico

Country Status (28)

Country Link
US (1) US20100016366A1 (es)
EP (1) EP2328868A1 (es)
JP (1) JP2011528346A (es)
KR (1) KR20110017452A (es)
CN (1) CN102099334A (es)
AP (1) AP2010005512A0 (es)
AR (1) AR072802A1 (es)
AU (1) AU2009272303B2 (es)
BR (1) BRPI0915753A2 (es)
CA (1) CA2727769A1 (es)
CL (1) CL2011000093A1 (es)
CO (1) CO6321246A2 (es)
CR (1) CR11828A (es)
DO (1) DOP2011000017A (es)
EA (1) EA201001842A1 (es)
EC (1) ECSP11010753A (es)
HN (1) HN2009001330A (es)
IL (1) IL210293A0 (es)
MA (1) MA32479B1 (es)
MX (1) MX2011000588A (es)
NI (1) NI201100015A (es)
NZ (1) NZ589934A (es)
PE (1) PE20110312A1 (es)
SV (1) SV2011003808A (es)
TW (1) TW201006799A (es)
UY (1) UY31980A (es)
WO (1) WO2010007552A1 (es)
ZA (1) ZA201100841B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083387A1 (en) * 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
CA2795253A1 (en) * 2010-04-01 2011-10-06 Theravida, Inc. Methods of improving quality of sleep
WO2016155573A1 (zh) * 2015-03-27 2016-10-06 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
WO2016180348A1 (zh) * 2015-05-14 2016-11-17 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的含氮杂螺环衍生物及其在医药上的用途
CN106336406B (zh) * 2015-07-10 2020-01-03 四川海思科制药有限公司 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途
ES2927715T3 (es) 2017-10-05 2022-11-10 Fulcrum Therapeutics Inc Inhibidores de la quinasa p38 reducen la expresión de dux4 y de los genes que le siguen para el tratamiento de la FSHD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP2013172A4 (en) * 2006-04-24 2010-08-04 Astrazeneca Ab NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE

Also Published As

Publication number Publication date
SV2011003808A (es) 2011-03-23
JP2011528346A (ja) 2011-11-17
NI201100015A (es) 2011-08-05
CA2727769A1 (en) 2010-01-21
IL210293A0 (en) 2011-03-31
TW201006799A (en) 2010-02-16
NZ589934A (en) 2012-06-29
UY31980A (es) 2010-02-26
MA32479B1 (fr) 2011-07-03
KR20110017452A (ko) 2011-02-21
MX2011000588A (es) 2011-03-01
CN102099334A (zh) 2011-06-15
AU2009272303B2 (en) 2011-12-22
CO6321246A2 (es) 2011-09-20
EP2328868A1 (en) 2011-06-08
CL2011000093A1 (es) 2011-05-06
PE20110312A1 (es) 2011-06-25
AR072802A1 (es) 2010-09-22
AU2009272303A1 (en) 2010-01-21
AP2010005512A0 (en) 2010-12-31
HN2009001330A (es) 2012-04-02
BRPI0915753A2 (pt) 2015-11-03
DOP2011000017A (es) 2011-02-15
US20100016366A1 (en) 2010-01-21
WO2010007552A1 (en) 2010-01-21
EA201001842A1 (ru) 2011-08-30
ECSP11010753A (es) 2011-02-28
ZA201100841B (en) 2011-10-26

Similar Documents

Publication Publication Date Title
CR9814A (es) Derivados de carboxamida como antagonistas del receptor muscarinico
CR20110233A (es) Nuevos compuestos halosustituidos
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
HN2010001563A (es) Compuestos
ECSP11011517A (es) Compuestos antivirales
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
CR11776A (es) Inhibidores de bace
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
ECSP11011390A (es) Compuestos espiro-amidas sustituidas
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
CR11742A (es) Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6
DOP2013000307A (es) Antagonistas de trpv4
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
ECSP10010200A (es) Derivados de pirazol como inhibidores de 5-lo
DOP2011000017A (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
HN2009003357A (es) Nuevos compuesto ligandos del receptor de la adenosina a3
UY32983A (es) Fungicidas de azolil benceno sustituido por heterobiciclos
UY31338A1 (es) Compuestos novedosos activos como antagonistas de receptores muscarinicos
DE602007005387D1 (de) Ptors
BR112012030004A2 (pt) antagonistas não competitivos de receptor nicotínico
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
CU23564A3 (es) Derivados de carboxamida como antagonistas del receptor muscarínico
CU20100105A7 (es) Derivados de pirazol como inhibidores de 5-lo

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)